ES2618352T3 - Antagonistas del receptor de prostaglandina D2 para el tratamiento de la alopecia androgenética - Google Patents

Antagonistas del receptor de prostaglandina D2 para el tratamiento de la alopecia androgenética Download PDF

Info

Publication number
ES2618352T3
ES2618352T3 ES07809581.7T ES07809581T ES2618352T3 ES 2618352 T3 ES2618352 T3 ES 2618352T3 ES 07809581 T ES07809581 T ES 07809581T ES 2618352 T3 ES2618352 T3 ES 2618352T3
Authority
ES
Spain
Prior art keywords
methyl
benzoyl
ylmethoxy
indole
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07809581.7T
Other languages
English (en)
Inventor
Luis Garza
George Cotsarelis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Application granted granted Critical
Publication of ES2618352T3 publication Critical patent/ES2618352T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0627—Hair cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Environmental Sciences (AREA)
  • Animal Husbandry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Un antagonista del receptor de prostaglandina D2 (receptor DP) para su uso en el tratamiento de la alopecia androgenética (AAG) en el cuero cabelludo de un sujeto.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
En otra realización, el antagonista del receptor DP es una variante de la estructura anterior, en la que el grupo ciclopentilo de la derecha arriba está sustituido por un grupo ciclohexilo. Cada uno de los sustituyentes enumerados 5 para la estructura anterior puede usarse para esta estructura que contiene ciclohexilo.
En otra realización, el antagonista del receptor DP tiene una de las siguientes estructuras:
imagen7
7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
En otras realizaciones, el antagonista del receptor DP es una sal no tóxica de uno de los compuestos anteriores.
En otras realizaciones, el antagonista del receptor DP se selecciona entre los siguientes compuestos: (1) éster bencílico del ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético,
(2)
ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (3) ácido 1-(4-((2R)-1,4-benzodioxan-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (4) ácido 1-(4-((2S)-1,4-benzodioxan-2ilmetoxi)benzoil)-2-metil-1H-indolo-4-il-acético, (5) ácido 1-(4-((2S)-1-metilindolin-2-ilmetoxi)benzoil)-2-metil-1H-indol4-il-acético, (6) ácido 1-(4-((2R)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (7) ácido 1-(4-((2S)-4,6-dimetil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (8) ácido 1-(4-((2S)-6-fluoro-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (9) ácido 1-(4-((2S)-6-metoxi-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (10) ácido 1-(4-((2S)-7-metoxi-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (11) ácido 1-(4-((2S)-4,7-dimetil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4ilacético, (12) ácido 1-(4-((2 S)-7-fluoro-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4il-acético, (13) ácido 1-(4-((2S)-1-etilindolin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (14) ácido 1-(4-((2S)-4,8dimetil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (15) ácido 1-(4-((2S)-5-metoxi4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (16) ácido 1-(4-((2S)-5-fluoro4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (17) ácido 1-(4-((2S)-2,3dihidrobenzofuran-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (18) ácido 1-(4-((2R)-2,3-dihidrobenzofuran-2ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (19) ácido 1-(4-((2S)-8-fluoro-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (20) ácido 1-(4-((2R)-1,4-benzoxatian-2-ilmetoxi)benzoil)-2-metil-1Hindol-4-il-acético, (21) ácido 1-(4-((3S)-2,3-dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (22) ácido 1-(4-((3R)-2,3-dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (23) ácido 1-(4-((3R)-5-fluoro2,3-dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (24) ácido 1-(4-((3R)-5-metil-2,3dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (25) ácido 1-(4-((3R)-6-fluoro-2,3dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (26) ácido 1-(4-((3R)-7-metil-2,3dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (27) ácido 1-(4-((2R)-5-fluoro-1,4-benzodioxan-2ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (28) ácido 1-(4-((2S)-8-fluoro-1,4-benzodioxan-2-ilmetoxi)benzoil)-2metil-1H-indol-4-il-acético, (29) ácido 1-(4-((3R)-7-fluoro-2,3-dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4il-acético, (30) éster alílico del ácido 3-(1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil1H-indol-4-il)acrílico, (31) ácido 3-(1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1Hindol-4-il)acrílico, (32) ácido 3-(1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol4-il)propanoico, (33) éster bencílico del ácido (1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2metil-1H-indol-4-il)oxiacético, (34) ácido (1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil1H-indol-4-il)oxiacético, (35) éster bencílico del ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2ilmetoxi)benzoil)-2-metil-1H-indol-4-carboxílico, (36) ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2ilmetoxi)benzoil)-2-metil-1H-indol-4-carboxílico, (37) éster bencílico del ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4benzoxazin-2-ilmetoxi)benzoil)-1H-indol-4-il-acético, (38) ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2ilmetoxi)benzoil)-1H-indol-4-il-acético, (39) ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)2,3-dihidro-1H-indol-4-il-acético, (40) ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2metil-2,3-dihidro-1H-indol-4-il-acético, (41) 2-(1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2metil-1H-indol-4-il)etanol, (42) 2-(1-(4-((2S)-4,6-dimetil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1Hindol-4-il)etanol, (43) 2-(1-(4-((2S)-6-fluoro-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1Hindol-4-il)etanol, (44) 2-(1-(4-((2S)-7-fluoro-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1Hindol-4-il)etanol, (45) 2-(1-(4-((2S)-2,3-dihidrobenzofuran-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il)etanol, (46) 2-(1-(4((3R)-2,3-dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4-il)etanol, (47) N-metilsulfonil-( 1-(4-((2S)-4-metil3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il)acetamida, (48) N-fenilsulfonil-(1-(4-((2S)-4metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il)acetamida, (49) acetato de 2-(1-(4-((2S)4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il)etilo, (50) éster bencílico del ácido 1(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)-2-metilbenzoil)-2-metil-1H-indol-4-il-acético, (51) éster bencílico del ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)-2-metilbenzoil)-1H-indol-4-il-acético,
(52)
ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)-2-metilbenzoil)-2-metil-1H-indol-4-il-acético, y
(53)
ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)-2-metilbenzoil)-1H-indol-4-il-acético o una sal no tóxica de los mismos.
En otras realizaciones, el antagonista del receptor DP tiene la estructura:
21
imagen21
en la que
R.sup.1 representa hidroxi, alcoxi C1-6, o NR.sup.8R.sup.9, en la que cada uno de R.sup.8 y R.sup.9 representa independientemente un átomo de hidrógeno, alquilo C1-6, o SO.sub.2R.sup.13, en la que R.sup.13 representa alquilo C1-6, un anillo carbocíclico saturado o insaturado C3-15 o un anillo heterocíclico de 4 a 15 miembros que contiene de 1 a 5 átomos de nitrógeno, átomos de azufre y/o átomos de oxígeno; R.sup.2 representa un átomo de hidrógeno, alquilo C1-6, alcoxi C1-6, alcoxialquilo C2-6, un átomo de halógeno, amino, trihalometilo, ciano, hidroxi, bencilo, o 4-metoxibencilo; R.sup.3 representa un átomo de hidrógeno, alquilo C1-6, alcoxi C1-6, un átomo de halógeno, trihalometilo, ciano, o hidroxi; cada uno de R.sup.4 y R.sup.5 representa independientemente un átomo de hidrógeno, alquilo C1-6, alcoxi C1-6, alcoxialquilo C2-6, un átomo de halógeno, nitro, amino, trihalometilo, ciano, o hidroxi; D representa un enlace sencillo, alquileno C1-6, alquenileno C2-6, u oxialquileno C1-6; en --G--R.sup.6,
1) G representa un enlace sencillo, alquileno C1-6 que puede estar sustituido con 1 a 2 átomos de oxígeno y/o átomos de azufre, alquenileno C2-6 que puede estar sustituido con 1 a 2 átomos de oxígeno y/o átomos de azufre, en la que el alquileno y el alquenileno pueden estar sustituidos con hidroxi o alcoxi C1-4, --C(O)NH--, --NHC(O)--, -SO.sub.2NH--,-NHSO.sub.2--, o diazo; R.sup.6 representa un anillo carbocíclico saturado o insaturado C3-15, o un anillo heterocíclico de 4 a 15 miembros que contiene de 1 a 5 átomos de nitrógeno, átomos de azufre y/o átomos de oxígeno, en la que el anillo puede estar sustituido con 1 a 5 sustituyentes seleccionados entre alquilo C1-6, alcoxi C1-10, alcoxialquilo C2-6, un átomo de halógeno, hidroxi, trihalometilo, nitro, amino, fenilo, fenoxi, oxo, acilo C2-6, alcanosulfonilo C1-6 y ciano,
2) G y R.sup.6 se toman juntos para representar
(i)
alquilo C1-15 que puede estar sustituido con 1 a 5 átomos de oxígeno y/o átomos de azufre;
(ii)
alquenilo C2-15 que puede estar sustituido con 1 a 5 átomos de oxígeno y/o átomos de azufre; o
(iii) alquinilo C2-15 que puede estar sustituido con 1 a 5 átomos de oxígeno y/o átomos de azufre, en la que el alquilo, el alquenilo y el alquinilo pueden estar sustituidos con 1 a 12 sustituyentes seleccionados entre alcoxi C1-6, un átomo de halógeno, hidroxi, ciano, oxo y NR.sup.11R.sup.12, en la que cada uno de R.sup.11 y R.sup.12 representa independientemente un átomo de hidrógeno, alquilo C1-6, alquenilo C2-6, fenilo, benzoílo, naftilo, fenilo sustituido con alquilo C1-6, o alquilo C1-6 sustituido con fenilo o ciano; n representa de 1 a 3; m representa de 1 a 3; i representa de 1 a 4; y
22
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46

Claims (1)

  1. imagen1
ES07809581.7T 2006-06-16 2007-06-15 Antagonistas del receptor de prostaglandina D2 para el tratamiento de la alopecia androgenética Active ES2618352T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US81404106P 2006-06-16 2006-06-16
US814041P 2006-06-16
US84516106P 2006-09-18 2006-09-18
US845161P 2006-09-18
PCT/US2007/014031 WO2007149312A2 (en) 2006-06-16 2007-06-15 Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph

Publications (1)

Publication Number Publication Date
ES2618352T3 true ES2618352T3 (es) 2017-06-21

Family

ID=38833999

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07809581.7T Active ES2618352T3 (es) 2006-06-16 2007-06-15 Antagonistas del receptor de prostaglandina D2 para el tratamiento de la alopecia androgenética

Country Status (10)

Country Link
US (3) US9254293B2 (es)
EP (2) EP3175856A1 (es)
CY (1) CY1118737T1 (es)
DK (1) DK2037967T3 (es)
ES (1) ES2618352T3 (es)
HU (1) HUE030850T2 (es)
PL (1) PL2037967T3 (es)
PT (1) PT2037967T (es)
SI (1) SI2037967T1 (es)
WO (1) WO2007149312A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241696A1 (en) * 2005-04-26 2006-10-26 Stjepan Krco Method of limiting hair loss and promoting hair growth
US20150072963A1 (en) * 2006-06-16 2015-03-12 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating hair growth
DK2037967T3 (en) 2006-06-16 2017-03-13 Univ Pennsylvania PROSTAGLANDIN-D2 RECEPTOR ANTAGONISTS FOR TREATMENT OF ANDROGENETIC ALOPECI
US8455547B2 (en) * 2008-02-05 2013-06-04 Allergan, Inc. Substituted cyclopentanes having prostaglandin activity
US8748177B2 (en) * 2008-09-30 2014-06-10 The Hospital For Sick Children Compositions for proliferation of cells and related methods
WO2012078649A1 (en) 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
CN104602763B (zh) * 2012-03-21 2018-08-21 宾夕法尼亚大学理事会 用于调节毛发生长的组合物和方法
FR3000396A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et de doxycycline pour le traitement de la rosacee
FR3000397A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
FR3000395A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'oxymetazoline pour le traitement de la rosacee
FR3000394A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et de metronidazole pour le traitement de la rosacee
FR3000399B1 (fr) * 2012-12-31 2015-03-27 Galderma Res & Dev Utilisation topique du laropiprant pour le traitement de la rosacee
FR3000398A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et de brimonidine pour le traitement de la rosacee
EP3382391A1 (en) 2012-10-24 2018-10-03 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
WO2014079805A1 (en) * 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Pyrazole compounds for treating hairloss
US20140148470A1 (en) 2012-11-23 2014-05-29 Boehringer Ingelheim International Gmbh Pyrimidine compounds for treating hairloss
WO2014079803A1 (en) 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Bicyclosubstituted pyrazole compounds for treating hairloss
US10080771B2 (en) * 2015-01-28 2018-09-25 The Trustees Of The University Of Pennsylvania Compositions and methods for generation of human epithelial stem cells
CN108472510A (zh) * 2015-07-30 2018-08-31 宾夕法尼亚大学理事会 用于检测pgd2对毛发生长抑制的易感性的人dp-2基因的单核苷酸多态性等位基因
WO2019050480A1 (en) * 2017-09-07 2019-03-14 Agency For Science, Technology And Research METHODS FOR SCREENING AGENTS FOR CONTROLLING HAIR / HAIR PUSH OR HAIR / HAIR CYCLE
KR20200109293A (ko) 2017-09-13 2020-09-22 프로제너티, 인크. 자간전증 바이오마커 및 관련된 시스템 및 방법
KR101857408B1 (ko) * 2018-02-28 2018-05-14 경북대학교 산학협력단 탈모 예방 또는 치료용 조성물
US10835538B2 (en) * 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics
US20220143153A1 (en) * 2019-03-08 2022-05-12 The Regents Of The University Of California Compositions and methods for treating acne
CN110278919A (zh) * 2019-07-30 2019-09-27 罗洋 一种构建蠕形螨致玫瑰痤疮样皮损动物模型的方法
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
JP2023532888A (ja) * 2020-06-27 2023-08-01 クレセンタ バイオサイエンシズ 細胞代謝を調節する化合物の組成及び使用方法
WO2023060320A1 (en) * 2021-10-15 2023-04-20 Bod Science Limited Topical protein based formulation

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI872553A (fi) 1986-06-09 1987-12-10 American Cyanamid Co Medium foer laekemedel foer lokalt bruk.
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
CN1179945C (zh) 2000-03-09 2004-12-15 小野药品工业株式会社 吲哚衍生物、其制备方法及用途
WO2003022814A1 (fr) 2001-09-07 2003-03-20 Ono Pharmaceutical Co., Ltd. Derives d'indole
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
FR2812192B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
JP2004513660A (ja) 2000-11-22 2004-05-13 トリリウム　セラピューティクス　インコーポレーティッド 切断型ｃｄ２００
AU2002257132A1 (en) 2001-04-06 2002-10-21 The Trustees Of The University Of Pennsylvania Erbb interface peptidomimetics and methods of use thereof
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
DK1482973T3 (da) 2002-03-15 2009-12-07 Schering Corp Fremgangsmåde til modulering af CD200-receptorer
ATE516277T1 (de) 2002-03-19 2011-07-15 Ono Pharmaceutical Co Carbonsäureverbindungen und arzneimittel, die diese verbindungen als wirkstoffe enthalten
WO2003097042A1 (fr) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Antagoniste de recepteur de pdg2
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
AU2003265264A1 (en) 2002-07-09 2004-01-23 Point Therapeutics, Inc. Methods and compositions relating to isoleucine boroproline compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
KR20050055747A (ko) 2002-10-04 2005-06-13 밀레니엄 파머슈티컬스 인코퍼레이티드 염증 질환 치료용의 ｐｇｄ2 수용체 길항제
BR0315547A (pt) 2002-10-21 2005-09-20 Warner Lambert Co Derivados de quinolina como antagonistas de crth2
FI116400B (fi) 2002-11-19 2005-11-15 Metso Paper Inc Paperi- tai kartonkikoneen puristinosa
MXPA05006978A (es) * 2002-12-27 2005-08-16 Schering Corp Metodos para inducir y mantener la tolerancia inmune.
EP1435356A1 (en) 2003-01-06 2004-07-07 Warner-Lambert Company LLC Quinoline derivatives as CRTH2 antagonists
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
SE0302232D0 (sv) * 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
WO2005028455A1 (ja) 2003-09-17 2005-03-31 Ono Pharmaceutical Co., Ltd. カルボン酸化合物およびそれらを有効成分として含有する医薬組成物
US20070232681A1 (en) 2003-10-14 2007-10-04 Oxagen Limited Compounds Having Crth2 Antagonist Activity
WO2005040112A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
GB2407318A (en) 2003-10-23 2005-04-27 Oxagen Ltd Substituted Indol-3-yl acetic acid derivatives
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
US20050112075A1 (en) * 2003-11-25 2005-05-26 Hwang Cheng S. Reduction of hair growth
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
DK1725553T3 (da) 2004-03-11 2008-08-18 Actelion Pharmaceuticals Ltd Tetrahydropyridoindolderivater
KR20070002085A (ko) 2004-04-07 2007-01-04 밀레니엄 파머슈티컬스 인코퍼레이티드 염증 질병을 치료하기 위한 ｐｇｄ２ 수용체 길항제
EP1740179A1 (en) 2004-04-20 2007-01-10 Pfizer Limited Method of treating neuropathic pain using a crth2 receptor antagonist
US7405215B2 (en) 2004-09-21 2008-07-29 Wyeth Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
EP1830793A1 (en) 2004-12-29 2007-09-12 R-Tech Ueno, Ltd. Composition and method for scalp and hair treatment
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
CA2603365C (en) 2005-03-29 2017-06-06 The Trustees Of The University Of Pennsylvania Methods for generating new hair follicles, treating baldness, and hair removal
EP1882937B1 (en) 2005-05-17 2012-02-22 Taiho Pharmaceutical Co., Ltd. Method for diagnosis of severity and prediction of recurrence in eosinophilic inflammatory disease
RU2333763C2 (ru) 2006-02-27 2008-09-20 Дмитрий Николаевич Мясников Средство для профилактики и лечения андрогенной алопеции, очагового и себорейного облысения, жирной и густой себореи волосистой части головы, перхоти и способ его получения
GB0605743D0 (en) 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
DK2037967T3 (en) 2006-06-16 2017-03-13 Univ Pennsylvania PROSTAGLANDIN-D2 RECEPTOR ANTAGONISTS FOR TREATMENT OF ANDROGENETIC ALOPECI
EP2046740B1 (en) 2006-07-22 2012-05-23 Oxagen Limited Compounds having crth2 antagonist activity
JP2012530492A (ja) 2009-06-17 2012-12-06 アデランス リサーチ インスティテュート，インコーポレイティド 真皮細胞の発毛促進能を増大させるための方法および組成物
SG177736A1 (en) 2009-07-31 2012-02-28 Panmira Pharmaceuticals Llc Dermal formulations of dp2 receptor antagonists
US8771765B1 (en) 2009-12-22 2014-07-08 Ailin Fernandez Method and composition for treatment of hair loss
US20100172865A1 (en) 2010-03-18 2010-07-08 Shantha Totada R Methods of enhancing hair growth
WO2012078649A1 (en) 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
CN104602763B (zh) 2012-03-21 2018-08-21 宾夕法尼亚大学理事会 用于调节毛发生长的组合物和方法

Also Published As

Publication number Publication date
EP2037967A2 (en) 2009-03-25
EP2037967B1 (en) 2016-12-07
CY1118737T1 (el) 2018-03-07
US9254293B2 (en) 2016-02-09
WO2007149312A3 (en) 2009-04-02
US9889082B2 (en) 2018-02-13
HUE030850T2 (en) 2017-06-28
US20190380942A1 (en) 2019-12-19
US20160346186A1 (en) 2016-12-01
SI2037967T1 (sl) 2017-04-26
DK2037967T3 (en) 2017-03-13
EP3175856A1 (en) 2017-06-07
US20110021599A1 (en) 2011-01-27
EP2037967A4 (en) 2010-07-07
PL2037967T3 (pl) 2017-07-31
US10849841B2 (en) 2020-12-01
WO2007149312A2 (en) 2007-12-27
PT2037967T (pt) 2017-03-14

Similar Documents

Publication Publication Date Title
ES2618352T3 (es) Antagonistas del receptor de prostaglandina D2 para el tratamiento de la alopecia androgenética
RU2404979C2 (ru) 2,4-ди(аминофенил)пиримидины в качестве ингибиторов рlk-киназ
AR058401A1 (es) Pirimidinas sustituidas con sulfoximinas proceso para su produccion y uso de las mismas como farmacos
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
PE20070181A1 (es) DERIVADOS DE CICLOHEXILAMINISOQUINOLONA COMO INHIBIDORES DE Rho-QUINASA
AR032624A1 (es) Derivados de fenilamina ciclica, uso de los mismos para la fabricacion de medicamentos y composicion farmaceutica
AR058703A1 (es) Triazolopiridazinas inhibidoras de tirosinquinasas, metodo de preparacion, composiciones farmaceuticas que las contienen y usos terapeuticos en el tratamiento del cancer
AR048315A1 (es) Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas.
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
RU2004132204A (ru) Имидазоконденсированные соединения
AR048641A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame
AR039403A1 (es) Derivados de acil-4-carboxifenilurea y su uso como antidiabetico
AR055015A1 (es) Derivados fusionados de pirazol composicion farmaceutica y uso del compuesto para fabricar medicamentos.
AR050430A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
RU2008142600A (ru) Органическое соединение
AR047537A1 (es) Piridazinonaureas como antagonistas de integrinas
AR073688A1 (es) Agonistas de receptores cb2, derivados de oxazoles y/o triazoles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, enfermedades autoinmunes y alergicas, entre otras.
AR078786A1 (es) Derivados de la cromenona
AR039112A1 (es) Inhibidores de quinasas
AR051735A1 (es) Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos.
AR056691A1 (es) Derivados pirrolopirimidina como inhibidores de syk
JP2008510691A5 (es)
AR079553A1 (es) Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros.
PE20141674A1 (es) Derivados de heterociclos biciclicos para el tratamiento de la hipertension arterial pulmonar
AR044342A1 (es) Derivados de bencimidazol